On July 5, 2022 Brand Institute reported its work with Solasia Pharma K.K. ("Solasia") in developing the brand name DARVIAS (Press release, Brand Institute, JUL 5, 2022, View Source [SID1234616487]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

DARVIAS, an organoarsenic compound with anticancer activity, is a novel mitochondrial-targeted agent being developed for the treatment of various hematologic and solid tumors. DARVIAS provokes cell cycle arrest and apoptosis through disruption of mitochondrial functions and increased production of reactive oxygen species in tumor cells. DARVIAS is expected to exert an anticancer effect by inducing cell cycle arrest and apoptosis.

DARVIAS has been approved for relapsed or refractory Peripheral T-Cell Lymphoma by Japan’s Ministry of Health, Labour and Welfare (MHLW). Japan is the first country in the world where DARVIAS has been approved. DARVIAS has been granted orphan drug designation in the US and EU.

"The entire Brand Institute and Drug Safety Institute team congratulates Solasia on the MHLW approval of the DARVIAS injection," said Brand Institute’s Chairman and C.E.O., James L. Dettore.